> ## Content Index > Fetch the complete content index at: https://www.theamericanquorum.com/llms.txt > Use this file to discover other available public pages before exploring further. # FDA Clears 4 Alzheimer’s Blood Tests, but Screening Gap Remains - URL: https://www.theamericanquorum.com/fda-clears-4-alzheimers-blood-tests-screening-gap-remains/ - Published: 2026-09-13T08:27:39.000Z - Updated: 2026-09-13T08:27:39.000Z - Description: Four FDA-cleared blood tests can now help evaluate Alzheimer’s disease in symptomatic patients, but specialists caution they are not stand-alone screens for healthy adults. The distinction matters as demand moves faster than evidence. - Author: Kenneth R. Deans Jr. - Tags: Healthcare Blood tests are beginning to change how Alzheimer’s disease is evaluated in the United States, but the medical promise comes with a boundary that is easy to miss. The Food and Drug Administration has now cleared four blood-based tests to help clinicians assess people who already have signs of cognitive impairment. None is cleared as a stand-alone screening test for healthy people who simply want to know their future risk. That distinction moved to the center of a new [AP review](https://apnews.com/article/55eb2d490231b57acec8ef2848072d93?ref=theamericanquorum.com) published Saturday. Specialists told the news organization that symptom-free adults are seeking blood tests even though the results have not been validated to predict who will develop dementia. A positive biomarker can identify biological changes associated with Alzheimer’s, but it cannot by itself determine whether or when memory loss will occur. The tests remain a significant advance. They may reduce reliance on costly PET scans and invasive spinal taps, accelerate referrals and help clinicians determine whether a patient could qualify for therapies aimed at slowing early Alzheimer’s. But their arrival also creates a new problem for patients and primary-care doctors: a test can be technically accurate for a narrow clinical purpose while being misleading when used outside that purpose. ## Four tests, one important limitation The regulatory path began in May 2025, when the [FDA cleared](https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease?ref=theamericanquorum.com) the Lumipulse G pTau217/β-amyloid 1-42 plasma ratio. The device measures two proteins in blood and calculates a ratio associated with amyloid plaques in the brain. It was evaluated in adults 55 and older who had cognitive impairment and was intended for use in specialized care. In the FDA-reviewed study of 499 samples, 91.7% of people with a positive result had amyloid plaques confirmed by PET imaging or cerebrospinal-fluid testing, while 97.3% of those with a negative result lacked that evidence. Fewer than one in five results were indeterminate. Those figures demonstrate strong diagnostic performance in the population studied, not certainty for every patient. The agency explicitly said Lumipulse was not a screening or stand-alone diagnostic test. False positives could bring psychological distress, unnecessary treatment or a delay in finding another cause of symptoms. False negatives could postpone effective care. Clinical history, cognitive evaluation and sometimes additional testing remain necessary. The market expanded quickly. Roche’s Elecsys pTau181 test was cleared in 2025 to help rule out Alzheimer’s-related amyloid pathology. In August 2026, regulators cleared C2N Diagnostics’ PrecivityAD2 and Roche’s Elecsys pTau217\. The latest Roche test can support both rule-in and rule-out assessment for patients with cognitive decline, according to the [Alzheimer’s Association](https://www.alz.org/news/2026/fda-clearance-elecsys-ptau217-blood-test-alzheimers?ref=theamericanquorum.com). ## Why symptoms change the meaning A test’s predictive value depends partly on how likely the disease was before testing. In a memory clinic, a patient with persistent cognitive changes has a higher pretest probability of Alzheimer’s pathology than an asymptomatic adult ordering a test out of curiosity. The same laboratory result can therefore carry a different likelihood of being clinically meaningful. Alzheimer’s-related amyloid and tau changes can begin years before noticeable symptoms. Yet some people with abnormal biomarkers may remain cognitively healthy for a long time, while others will develop impairment from vascular disease, Lewy body disease, medication effects, depression, sleep disorders or other causes. A blood result does not replace the work of separating those possibilities. The [clinical guideline](https://www.alz.org/alz-pro/hub/care-pathway/blood-based-biomarkers-guideline?ref=theamericanquorum.com) issued by the Alzheimer’s Association is therefore deliberately narrow. It covers patients with cognitive impairment in specialty settings and recommends tests according to minimum standards for sensitivity and specificity. It also emphasizes informed consent, patient-centered communication and interpretation within a complete diagnostic evaluation. The broader [diagnostic process](https://www.alz.org/alzheimers-dementia/diagnosis/medical%5Ftests?ref=theamericanquorum.com) may include medical and family history, neurological examination, cognitive and functional assessment, laboratory work and brain imaging. Some causes of dementia-like symptoms—including thyroid problems, medication side effects, vitamin deficiencies, depression and untreated sleep apnea—may be treatable or reversible. Skipping that evaluation can turn a convenient blood test into a clinical shortcut. ## Access is widening faster than experience The newest tests could make biomarker evaluation available beyond major academic memory centers. Roche said its pTau217 assay can run on thousands of existing laboratory analyzers, and Labcorp and Quest planned to offer it through national networks, according to [Reuters](https://www.reuters.com/legal/litigation/roche-eli-lillys-alzheimers-blood-test-gets-fda-clearance-2026-08-24/?ref=theamericanquorum.com). PrecivityAD2 is based on technology developed at Washington University in St. Louis and measures a combination of phosphorylated tau and amyloid signals, [WashU reported](https://medicine.washu.edu/news/fda-clears-blood-test-to-aid-evaluation-for-alzheimers-disease/?ref=theamericanquorum.com). Wider access matters because traditional confirmation can be burdensome. PET scanners are not available in every community, and lumbar punctures require specialized procedures. A standard blood draw can be performed in many clinics and may help physicians identify which patients need further evaluation rather than sending everyone directly to higher-cost testing. But scale can magnify misuse. Online marketing may blur the difference between detecting pathology and forecasting dementia. Primary-care practices may have less experience discussing indeterminate results or arranging confirmatory workups. Patients may also interpret a biomarker result as a diagnosis, even when a laboratory report and the FDA label say otherwise. The [National Institute](https://www.nia.nih.gov/health/cognitive-assessment-considerations-understanding-evidence?ref=theamericanquorum.com) on Aging has warned that testing people unlikely to have cognitive impairment can generate false positives and unnecessary worry. It notes that federal evidence reviews have not established that routine cognitive screening of asymptomatic older adults produces more benefit than harm. Blood biomarkers add new tools, but they do not erase that evidence gap. ## Prevention has stronger evidence than prediction For people without symptoms, the more useful response is often less technologically dramatic. A long-running study of more than 12,000 adults found that normal blood pressure, absence of diabetes and not smoking in midlife were associated with nearly 13 additional years of life without dementia compared with having all three risk factors. The [AAN summary](https://www.aan.com/PressRoom/Home/PressRelease/5357?ref=theamericanquorum.com) cautioned that the observational study showed association rather than proof of causation. That result reinforces a larger body of research connecting brain health with cardiovascular and metabolic health. Blood pressure control, diabetes management, smoking cessation, physical activity and treatment of hearing or vision loss are not guarantees against dementia. They are practical interventions with benefits that extend beyond cognition to stroke, heart disease and overall longevity. The 2024 [Lancet Commission](https://pubmed.ncbi.nlm.nih.gov/39096926/?ref=theamericanquorum.com) identified 14 potentially modifiable risk factors across the life course, including lower education, hearing loss, high LDL cholesterol, depression, traumatic brain injury, physical inactivity, diabetes, smoking, hypertension, obesity, excessive alcohol use, social isolation, air pollution and untreated vision loss. Its population estimate suggested that addressing all 14 could prevent or delay about 45% of dementia cases. That 45% figure is theoretical and population-based. It does not mean an individual can reduce personal risk by exactly that amount, and it should not be used to blame people who develop dementia. Age and genetics remain important, access to prevention is unequal, and many people develop disease despite healthy behavior. ## What patients and clinicians should do now People noticing persistent changes in memory, language, judgment or daily function should seek a medical evaluation rather than order an isolated test. A clinician can look for reversible causes, document whether impairment is present and decide whether a blood biomarker, imaging study or specialist referral would meaningfully change care. For an asymptomatic person concerned because of age or family history, the present evidence supports a different conversation: review blood pressure, glucose, cholesterol, smoking, exercise, sleep, hearing, vision, mood and social connection. Genetic counseling may be appropriate in some families, but consumer testing should not be confused with a clinical diagnosis or a forecast. Research may eventually support biomarker screening before symptoms. Trials are testing whether treating biologically defined Alzheimer’s at that stage can delay cognitive decline. Until those studies show that earlier detection leads to better outcomes—and clarify the harms of false or uncertain results—the regulatory boundary remains medically important. Alzheimer’s blood tests have crossed a threshold from research tool to clinical instrument. Their value is real: they can make a difficult diagnosis faster, less invasive and potentially more accessible. Their limitation is equally real: a test designed to clarify symptoms is not yet a crystal ball for healthy adults. The most evidence-based use of the new technology begins with knowing that difference.